DaVita (DVA) drew fresh attention after its recent share move, with the stock closing at US$180.40 as of 6 October 2026. This prompted investors to reassess its kidney care focused business.
Recent trading has been choppy for DaVita. The 1 day share price return of 0.94% and 7 day share price gain of 2.97% followed a 90 day share price decline of 21.81%. At the same time, the year to date share price return of 57.54% and 3 year total shareholder return of 97.63% point to momentum that has built over a longer stretch.
Scan how DaVita’s recent swings compare with other potential opportunities by checking out a curated list of 26 high quality undervalued stocks that are showing stronger value signals right now.
DaVita’s sharp pullback over the past quarter sits beside strong multi year returns and a 2026 rebound. Is this the moment to step in? Or does patience make more sense once the valuation work is done?
Most Popular Narrative: 18% Undervalued
DaVita’s most followed narrative pegs fair value at about $219.86 per share, well above the recent $180.40 close. This puts the focus firmly on how its kidney care model can support future cash flows under tighter reimbursement.
The Integrated Kidney Care business is achieving the highest aggregate savings in its CMS program with improved quality scores and is expected to add roughly US$20 million of adjusted operating income growth in 2026 and around 1 percentage point of ongoing operating income contribution, which can support DaVita’s earnings even if U.S. dialysis reimbursement remains tight.
See why 20 investors see DaVita as 18% undervalued.
Result: Fair Value of $219.86 (UNDERVALUED)
Still, the DaVita story could crack if U.S. reimbursement updates lag rising costs, or if payer mix shifts cut into revenue per treatment more than expected.
Find out about the key risks to this DaVita narrative.
Next Steps
Mixed sentiment around DaVita’s recent moves is clear. Act while the data is fresh and weigh both sides through the 3 key rewards and 1 important warning sign.
Ready for more investment ideas beyond DaVita?
Do not stop with DaVita. Put the same disciplined mindset to work across fresh ideas that could suit your goals, risk comfort, and time horizon.
- Target potential mispricing by scanning a focused set of companies screened as 26 high quality undervalued stocks before the rest of the market catches on.
- Prioritise resilience by sifting through a list of solid balance sheet and fundamentals (25 results) that can handle shocks better than overleveraged peers.
- Hunt for tomorrow's stories early by reviewing a curated pool of 19 high quality undiscovered gems while they are still off most investors' radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com